FATE THERAPEUTICS INC (FATE) Stock News
NASDAQ:FATE - Nasdaq - US31189P1021 - Common Stock - Currency: USD
FATE Latest News, Press Relases and Analysis
Fate Therapeutics' Q1 Earnings & Revenues Beat, Pipeline in Focus
FATE incurs a narrower-than-expected loss in the first quarter. The company's innovative pipeline remains in focus.
Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates
Additional Phase 1 Data for FT819 Off-the-Shelf CAR T-cell Product Candidate in Moderate-to-Severe Systemic Lupus Erythematosus to be Featured in Oral...
Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a...
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting
Updated clinical and preclinical data showcase iPSC-derived off-the-shelf CAR T-cell therapy products for conditioning chemotherapy-free treatment across autoimmune and cancer indications
Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting
Updated clinical and preclinical data showcase iPSC-derived off-the-shelf CAR T-cell therapy products for conditioning chemotherapy-free treatment across...
Fate Therapeutics Stock Draws Investor Attention After FDA Grants Special Designation To Its CAR T-Cell Therapy: Retail Stays Optimistic
CEO Bob Valamehr said the RMAT designation recognises the therapy's potential in treating lupus.
Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)
– Recognizes potential of off-the-shelf CAR T-cell therapy to address significant unmet need and enables increased dialogue with FDA throughout the...
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, April 02, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a...
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
Phase 1 Dose Expansion Initiated for FT819 Off-the-Shelf CAR T-cell Product Candidate with Fludarabine-free Conditioning in Moderate-to-Severe SLE ...
Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, March 04, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a...
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics to Present at Upcoming Investor Conferences
SAN DIEGO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a...
Fate Therapeutics to Present at Upcoming Investor Conferences
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a...
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a...
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus
All Three Patients Treated in First Dose Cohort Administered Fludarabine-free Conditioning and Show Rapid, Deep, and Sustained B-cell Depletion with...
Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a...
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics Announces Leadership Transition
Bob Valamehr, Ph.D. MBA, To Become President and CEO January 1, 2025 Scott Wolchko To Retire as President and CEO after 10 years of Leadership in...
Fate Therapeutics Announces Leadership Transition
Iris Energy, Arrowhead Pharmaceuticals, Urban Outfitters And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Wednesday.
Fate Therapeutics to Present at Upcoming December Investor Conferences
SAN DIEGO, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a...
Fate Therapeutics to Present at Upcoming December Investor Conferences
Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence
27-year-old African American-Asian Woman with Active Lupus Nephritis Achieved DORIS Clinical Remission; Patient Remains On-study, in Clinical Remission,...
Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence
Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates
Initial Clinical Data from Phase 1 Autoimmunity Study of FT819 1XX CAR T-cell Product Candidate to be Presented in 4Q24; Second Treatment Arm Adding FT819...